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Abstract
Background: Tumor cells need large energy and nucleic acids to proliferate and grow. For most
of their energy needs, cancer cells depend more on glycolysis. For most of their nucleic acids needs,
cancer cells depend more on the nonoxidative pathway of the pentose phosphate pathway.
Transketolase(TKT) is a crucial enzyme in the nonoxidative pathway of the PPP.
Methods: The real-time quantity PCR was used to determine the expression of transketolase gene
family in uterine cervix cancer. Transketolase activity of cell was determined by using enzyme-
linked method. Cell proliferation was detected by using MTT.
Results: The TKTL1 mRNA was specifically over-expressed in uterine cervix cancer cells(HeLa
cell line) compare with normal human endocervical epithelial cells(End1/E6E7 cell line)(P < 0.05),
whereas the expression of TKT and transketolase-like gene 2(TKTL2) have no significant
differences between the two cell lines(P > 0.05). Moreover, we found that total transketolase
activity was significantly reduced, and cell proliferation was remarkably inhibited after anti-TKTL1
siRNA treatment in HeLa cells. The total transketolase activity and cell proliferation have no
significant differences after anti-TKTL1 siRNA treatment in End1/E6E7 cells.
Conclusion: These results indicate that TKTL1 plays an important role in total transketolase
activity and cells proliferation in uterine cervix cancer.
Background
Tumor cells need more energy than normal cells to survive
and grow. For most of their energy needs, normal cells rely
on a process called respiration, which consumes oxygen
and glucose to make energy-storing molecules of adenos-
ine triphosphate (ATP). But cancer cells typically depend
more on glycolysis, the anaerobic breakdown of glucose
into ATP [1]. Warburg had identified a particular meta-
bolic pathway in carcinomas characterized by the anaero-
bic degradation of glucose even in the presence of oxygen
(known as the Warburg effect) 80 years ago [2]. Although
the molecular basis for the altered glucose metabolism
has not been identified yet, widespread clinical use of pos-
itron-emission tomography (PET) has confirmed that
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there exists enhanced glucose degradation in tumors [3].
At the annual meeting (2006) of American Association of
Cancer Research, Gottlieb launched a lecture with this
provocative claim: "I believe I'm working on the seventh
element, which is bioenergetics."
Tumor cells need large energy and nucleic acids to prolif-
erate and grow. The pentose phosphate pathway (PPP) is
an important pathway in glucose metabolism. Transketo-
lase is a crucial enzyme in the nonoxidative pathway of
the PPP. It plays a crucial role in nucleic acid ribose syn-
thesis utilizing glucose carbons in tumor cells. Boros[4]
found that more than 85% of ribose recovered from
nucleic acids of certain tumor cells is generated directly or
indirectly from the nonoxidative pathway of the PPP.
Three human transketolase genes have been recognized:
they are transketolase(TKT), transketolase-like gene 1
(TKTL1) and transketolase-like gene 2 (TKTL2). Lang-
bein[5] found that TKTL1 mRNA and protein are specifi-
cally over-expressed in tumors, whereas TKT and TKTL2
expression are not upregulated. Staiger[6] found that the
upregulation of TKTL1 is a common phenomenon in gas-
tric cancer and cancer of the gastroesophageal junction
leading to an enhanced, oxygen-independent glucose
usage which might contribute to a more aggressive tumor
growth.
Uterine cervix cancer is a common tumor in women. Dif-
fusion and metastasis play an important role in unfavour-
able prognosis of uterine cervix cancer. We knew little
about the mechanism of invasion and metastasis in uter-
ine cervix. Kohrenhagen[7] found that TKTL1 plays an
important role in the progression of cervical neoplasia.
But, the relative contributions of TKTL1 gene to energy
metabolism and cell proliferation in uterine cervix cancer
have not been investigated. In the present study, the rela-
tionship between transketolase-like gene 1 and transketo-
lase activity or cell proliferation was investigated in
uterine cervix cancer. These results indicate that TKTL1
gene influences cell proliferation by regulating total tran-
sketolase activity in human uterine cervix cancer cells.
Materials and methods
Reagent and Instrument
DMEM, Lipofectamine™ 2000 and Trizol were obtained
from Invitrogen Co (Carlsbad, CA, USA); Keratinocyte
serum-free medium (KER – SFM) were obtained from
GIBCO (New York, USA). ReverTraAce-α-™ (Reverse tran-
scription kit) were obtained from TOYOBO CO (Osaka,
Japan); Quanti Tect™ SYBR Green PCR kit was purchased
from Qiagen GmbH (Hilden, Germany); Coomassie Bril-
liant Blue G-250 was purchased from Amresco(USA);D-
Ribose 5-phosphate disodium salt, xylulose 5-phosphate
doium salt, triose-phosphate isomerase (TPI) and NADH
were obtained from Sigma Co (St Louis, MO, USA); FAC-
Scan Flow Cytometer (Becton Dickinson, USA); LightCy-
cler Real-Time PCR Instrument (Roche, Switzerland);
Olympus AU-2700 Autoanalyser (Toshiba, Japan).
Cell culture
HeLa cell line was obtained from the American Type Cul-
ture Collection (ATCC). It was originally established from
human cervix adenocarcinoma. Normal human endocer-
vical epithelial cell line (Endl/E6E7) was obtained from
Harvard Medical School. It was established by Fichorova
from normal human endocervical epithelial tissue in
1997[8]. HeLa cells were cultured in DMEM, Endl/E6E7
cells were cultured in KER-SFM medium supplemented
with 10%FCS at 37°C with 5% CO2.
Plasmid construction
The candidate siRNA sequence specific for human TKTL1
mRNA was selected and designed by using online tools
from Genesil Biotechnology Company. The selected can-
didate siRNA sequences were also checked to avoid any
possible match with other genes or polymorphism of the
target gene by Blast search. Three siRNA targeting human
TKTL1 mRNA (National Center for Biotechnology Infor-
mation access number: BC025382) and one scrambled
siRNA (used for a negative control) with the following
sequences were used: TKTL1 siRNA no.1, GCAGTCA-
GATCCAGAGAAT; TKTL1 siRNA no.2, GTTGGCAT-
GCAAAGCCAAT; TKTL1 siRNA no.3
CAACAGAGTCGTTGTGCTG; negative TKTL1 siRNA con-
trol, GACTTCATAAGGCGCATGC. All siRNA sequences
were synthesized by Wuhan Genesil Biotechnology Com-
pany, Wuhan, China. Synthetic sense and antisense oligo-
nucleotides constitute the template for generating RNA
composed of two identical 19-nt sequence motifs in an
inverted orientation, separated by a 9-bp (TTCAAGACA)
spacer to form a double strand hairpin of siRNA. Two
micrograms of both oligonucleotide were annealed for 3
minutes at 94°C, for 30 minutes at 37°C, and for 10 min-
utes at 65°C, then ligated into 2 μg of pEGFP-C1-U6 plas-
mid (containing kanamycin resistance gene; the mouse
U6 RNA Polymerase III promoter; enhanced green fluo-
rescence protein clone) linearized with BamHI and Hin-
dIII. These constructs were cloned to competent
Escherichia coli, according to the manufacture's instruc-
tions (Invitrogen). The sequences of the insert was con-
firmed by automated sequencing and by analyzing the
fragments generated from digestion with BamHI. The
resultant plasmids containing siRNA sequences 1, 2, 3 and
negative control sequences were named pSih TKTL1-1,
pSih TKTL1-2, pSih TKTL1-3 and pNC, respectively.
Transfection
HeLa Cells and End1/E6E7 cells were stably transfected
with three TKTL1 siRNA and a negative control siRNA in
presence of Lipofectamine 2000 on 6-well plates accord-Journal of Experimental & Clinical Cancer Research 2009, 28:43 http://www.jeccr.com/content/28/1/43
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ing to the manufacturer's instruction, respectively. Trans-
fected cells were selected for neomycin resistance in
DMEM containing G418 for 4 weeks. Surviving colonies
were isolated and expanded. These cells were harvested
and TKTL1 mRNA levels were analyzed by real-time PCR
at 96 h after cultured. Of the three plasmids tested, only
one gave rise to over 80% inhibition of TKTL1. We select
the plasmid named pSih TKTL1 to transfect HeLa Cells or
End1/E6E7 cells in the posterior experiment. The negative
control siRNA plasmid (without the shRNA coding DNA)
did not show any significant level of TKTL1 reduction.
RT-PCR
Total RNA was extracted from above-mentioned cells by
using Trizol reagent according to the manufacturer's
instructions. ReverTraAce-α-™ reverse transcription kit was
used for reverse transcription following instruction man-
ual. Real-time analysis was carried out on a Light Cycler
Real-Time PCR Instrument by using SYBR Green I dye
according to the manufacturer's protocol. Reactions were
performed in a 25 μL volume. Real-time PCR was con-
ducted by using the following parameters: denaturing at
94°C for 3 min, 40 cycles at 94°C for 5 s and at 57°C for
5 s. β-actin gene was used as an internal control and each
assay included standard samples in duplicates. Data anal-
ysis was carried out by using LightCycler Data Analysis
Software. In addition, PCR products were gel-separated to
confirm the bands of the expected size. Basically, quanti-
tative values are obtained from the threshold cycle
number at which the increase in the signal associated with
an exponential growth of PCR products starts to be
detected. Final results, expressed as N-fold differences in
target gene expression relative to the reference gene
GAPDH, termed 'Ntarget', were determined as follows:
Ntarget = 2(delta Ct sample - delta Ct reference gene).
Where delta Ct values of the sample and reference were
determined by subtracting the average Ct value of the test
gene from the average Ct value of the β-actin gene. The
sequence of primer for three known human transketolase
genes and β-actin were from reference.4. β-actin gene was
amplified as internal control. The sequences of primers
for TKT, TKTL1, TKTL2 were obtained by referring to Coy
et al [9]. The sequences of primers for β-actin gene: 5'-GTG
CGT GAC ATT AAG GAG-3'(sense), 5'-CTA AGT CAT AGT
CCG CCT-3'(antisense) were designed by using Primer
Premier 5.0 software package. The amplification condi-
tions: denaturing at 94°C for 3 min, 40 cycles at 94°C for
5 s and at 57°C for 5 s. The amplification products were
visualized by electrophoresis on a 1.5% agarose gel
stained with ethidium bromide.
Measurements of transketolase activity
In order to prepare the extract of HeLa and End1/E6E7
cells, cells were sonicated and centrifuged. The resulting
supernatant was filtered to remove some endogenous
metabolites. TK activity was determined by using enzyme-
linked method [4]. Samples were added to a cuvette con-
taining buffer (50 mM Tris/HCl, pH 7.6), 2 mM ribose 5-
phosphate, 1 mM xylulose 5-phosphate, 5 mM MgCl2, 0.2
U mL-1 of TPI, 0.2 mM NADH and 0.1 mM TPP. Reactions
were initiated by the addition of HeLa or End1/E6E7 cells
extract at 37°C. TK activity was expressed as ng product
per min per mg total protein. Total protein content of cell
extracts was determined by the Bradford method. Each
experiment was repeated three times.
Cell cycle analysis
104 cells of each group were seeded into a 6-well culture
plate. Then cells were harvested after cultured for 72
hours. The harvested cells were washed with PBS, fixed
with 70% alcohol, treated with RNase A and then stained
with propidium iodide. The analysis of cell cycle distribu-
tion was performed by FAC-Scan Flow Cytometer (Becton
Dickinson, USA) and analyzed by CellQuest software
package. Each experiment was repeated three times.
Cell proliferation assay
Cell proliferation was measured by the MTT assay. HeLa
and End1/E6E7 cells (cells without transfection, cells
transfected with control plasmid and cells transfected
with siRNA), at 2 × 103 per well, were seeded into five 96-
well culture plates, respectively. Each plate has three kinds
of cells (without transfection, transfected with control
plasmid or siRNA plasmid) and each group consisted of
12 parallel wells. Absorption value of one of five culture
plates was determined by MTT at 490 nm after 24-hour
cultivation. Then, absorption value of every culture plate
was detected in the following four days. The growth curve
of each group was plotted on the basis of absorption val-
ues. All experiments were done three times.
Statistical analysis
All results are expressed as means ± SD. Statistical analysis
was performed using the SPSS 10.0 software package for
Windows, and statistical significance was set at P < 0.05.
Results
Effects of TKTL1 siRNA on the Expression of transketolase 
gene family members in the human uterine cervix cancer 
and normal cervical epithelial cells
The relative expression level of each member of the tran-
sketlase gene family was determined by real-time PCR in
HeLa and End1/E6E7 cells. In the HeLa cells without
transfection, the expression level of the TKTL1 gene was
higher compared to the expression of TKT and TKTL2
gene. In the End1/E6E7 cells without transfection, the
expression level of the TKTL1 gene was lower compared to
the expression of TKT and TKTL2 gene. There was no sig-
nificant difference in the expression level of TKT and
TKTL2 gene between the HeLa and End1/E6E7 cells with-Journal of Experimental & Clinical Cancer Research 2009, 28:43 http://www.jeccr.com/content/28/1/43
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out transfection (P > 0.05). However, the expression level
of TKTL1 gene was significantly down-regulated in the
HeLa and End1/E6E7 cells transfected with siRNA TKTL1
construct compare with the cells transfected with control
plasmid or cells without transfection (P < 0.01). There was
no significant difference in the expression level of TKT and
TKTL2 gene among the cells without transfection, trans-
fected with control plasmid and transfected with siRNA in
the HeLa or End1/E6E7 cell line (Fig 1, Table 1).
Transketolase activity in human uterine cervix cancer and 
normal cervical epithelial cells
In order to estimate whether TKTL1 plays an important
role in the total transketolase activity in the uterine cervix
cancer and normal cervical epithelial cells, the total tran-
sketolase activity was measured in the cells without trans-
fection, transfected with control plasmid and transfected
with siRNA. We found that no significant difference
existed in total transketolase activity between HeLa cells
transfected with control plasmid and without transfec-
tion. In contrast, the total transketolase activity was signif-
icantly decreased in the HeLa cells transfected siRNA.
There were no significant difference existed in total tran-
sketolase activity among the End1/E6E7 cells without
transfection, transfected with control plasmid and trans-
fected with siRNA. The total transketolase activity was sig-
nificantly increased in the HeLa cells without transfection
compared to that in the End1/E6E7 cells without transfec-
tion. These results demonstrated that TKTL1 play a key
role in the total transketolase activity in the HeLa cells,
while it is not important in the total transketolase activity
in End1/E6E7 cells (Fig 2).
The effect of siRNA TKTL1 on cell cycle in HeLa and End1/
E6E7 cell line
To estimate the effect of siRNA TKTL1 on cell cycle we
transfected HeLa and End1/E6E7 cells using above differ-
ent plasmids, respectively. Each test was repeated three
times. In comparison to HeLa cells transfected with con-
trol plasmid, or cells without transfection, after transfec-
tion with siRNA TKTL1, the percentage of apoptotic cells
and G0/G1 stage cells was increased, and the percentage of
S stage cells showed no significant change, while the per-
centage of G2/M stage cells was significantly reduced.
There was no significant difference existed in cell cycle
among the End1/E6E7 cells without transfection, trans-
fected with control plasmid and transfected with siRNA
(Table 2).
The effect of siRNA TKTL1 on cell proliferation in HeLa 
and End1/E6E7 cell line
To examine the effect of siRNA TKTL1 on cell prolifera-
tion, the absorption values of one culture plate from each
group cells were detected by using MTT at 490 nm on
daily basis for a period of five days. The growth curve of
each cell group showed that cell proliferation was slower
in the HeLa cells transfected siRNA TKTL1 construct than
the cells transfected with control plasmid, or cells without
transfection (Fig 3). There was no significant difference of
cell proliferation among the End1/E6E7 cells without
transfection, transfected with control plasmid and trans-
fected with siRNA. Those results suggested that cells pro-
liferation was inhibited by transfected siRNA TKTL1
construct in the HeLa cells. While, there was no significant
difference on cell proliferation in normal cells after trans-
fected siRNA TKTL1 construct.
Discussion
Tumor cells need a large amount of energy and nucleic
acids to survive and grow. For most of their energy needs,
malignant cells typically depend on glycolysis mainly, the
anaerobic breakdown of glucose into ATP [1]. Malignant
cells characteristically exhibit an increased reliance on
anaerobic metabolism of glucose to lactic acid even in the
presence of abundant oxygen had been described by War-
burg 80 years ago [2]. But, this theory was gradually dis-
credited. Latter Following the development of
bioenergetics, recent studies demonstrated that energy
metabolism in malignant cells is significantly enhanced
compared to those in the normal cells, especially gly-
cometabolism [1]. The malignant cells maintain ATP pro-
duction by increasing glucose flux because anaerobic
metabolism of glucose to lactic acid is substantially less
efficient than oxidation to CO2 and H2O. PET imaging has
demonstrated a direct correlation between tumor aggres-
siveness and the rate of glucose consumption [10,11]. It is
now widely applied to human cancers because the vast
majority of primary and metastatic tumors demonstrate
substantially increased glucose uptake compared with
normal tissue. The majority of nucleic acids for tumor
cells growth are generated directly or indirectly from the
nonoxidative pathway of the PPP. Transketolase is a cru-
cial enzyme in the nonoxidative pathway of the PPP. It
has been presumed that transketolase activity possibly
plays an important role in the tumor cell proliferation.
Boros [4] found that the PPP was directly involved in deg-
radation of glucose and played a crucial role in nucleic
acid ribose synthesis utilising glucose carbons in tumor
cells. Coy [9] indicated that tumor cells which upregulate
transketolase enzyme reactions can use glucose as an
energy source through nonoxidative generation of ATP.
Using metabolic control analysis methods and oxythia-
mine, Comin-Anduix [12] demonstrated that transketo-
lase enzyme reactions determine cell proliferation in the
Ehrlich's ascites tumor model.
Ttransketolase gene family remember include transketo-
lase(TKT), transketolase-like gene 1 (TKTL1) and transke-
tolase-like gene 2 (TKTL2). The relative contributions of
transketolase gene family to energy metabolism and pro-Journal of Experimental & Clinical Cancer Research 2009, 28:43 http://www.jeccr.com/content/28/1/43
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Expression of transketolase gene family was analyzed by using gel electrophoresis in the End1/E6E7 cells and HeLa cells Figure 1
Expression of transketolase gene family was analyzed by using gel electrophoresis in the End1/E6E7 cells and 
HeLa cells. In the End1/E6E7 cells (A), the expression of TKT was significantly higher than the expression of TKTL1 and 
TKTL2. In the HeLa cells (B), the expression of TKTL1 was significantly higher than the expression of TKT and TKTL2. No 
expression of TKTL1 was found after transfected with siRNA in the End1/E6E7 cells and HeLa cells. β-actin: 520 bp, TKT: 176 
bp, TKTL1: 150 bp, TKTL2: 146 bp.Journal of Experimental & Clinical Cancer Research 2009, 28:43 http://www.jeccr.com/content/28/1/43
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liferation of uterine cervix cancer cell have not been inves-
tigated. In the present study, the total transketolase
activity was measured in the HeLa cells and End1/E6E7
cells. We found that the total transketolase activity was
significantly increased in the HeLa cells compare to End1/
E6E7 cells. In order to estimate whether TKTL1 play an
important role in the total transketolase activity in the
HeLa cells and End1/E6E7 cells, the relative expression
level of each member of the transketlase gene family was
determined by real-time PCR in HeLa and End1/E6E7
cells. We found that there was no significant difference in
the expression level of TKT and TKTL2 gene between the
HeLa and End1/E6E7 cells, the expression level of the
TKTL1 gene was high in the HeLa cells compared to End1/
E6E7 cells. After transfected siRNA TKTL1 construct, the
total transketolase activity was significantly decreased in
the HeLa cells. However, there was no significant differ-
ence existed in total transketolase activity in the End1/
E6E7 cells after transfected siRNA TKTL1 construct. These
results demonstrated that TKTL1 play a key role in the
total transketolase activity in the HeLa cells, yet not so in
the End1/E6E7 cells. In order to explore the effect of
TKTL1 on cell proliferation of cervix cancer cell, we trans-
fected the HeLa cells and End1/E6E7 cells with siRNA
TKTL1 construct. Our results demonstrated that the prolif-
eration of HeLa cells was significantly inhibited, and the
cells were blocked in G0/G1 stage. Whereas, there was no
significant change in cell proliferation and cell cycle in the
End1/E6E7 cells. So, we think that strong TKTL1 expres-
sion was correlated to fast proliferation of cervix cancer
cells. Lanbein [5] found that strong TKTL1 protein expres-
sion was correlated to invasive colon and urothelial
tumours and to poor patient outcome. Staiger [6] demon-
strated that TKTL1 upregulation is a common phenome-
non in gastric cancer and cancer of the gastroesophageal
junction. Földi indicated that TKTL1 expression in 86% of
breast cancer specimens with 45% showing high expres-
sion levels. Langbein[13] demonstrated that Transketo-
lase was more elevated in metastasizing renal cell cancer
and TKTL1 protein was significantly overexpressed in pro-
gressing renal cell cancer. Our previous study revealed that
TKTL1 play an important role in cell proliferation of colon
cancer, hepatoma and nasopharyngeal carcinoma [14-
16]. These results indicated that TKTL1 could be seen as a
potential target for novel anti-transketolase cancer thera-
pies.
In a word, TKTL1 plays an important role in total transke-
tolase activity and proliferation of tumor cells in uterine
cervix cancer. After the expression of TKTL1 was silenced,
the proliferation of uterine cervix cancer cells was
Table 1: The relative change in expression of transketolase gene family members in the human uterine cervix cancer and normal 
cervical epithelial cells
HeLa cells HeLa cells HeLa cells End1/E6E7 cells End1/E6E7 cells
Gene (No transfection) (control siRNA) (siRNA) (control siRNA) (siRNA)
TKT 1.05 ± 0.12 0.98 ± 0.09 1.06 ± 0.11 0.96 ± 0.10 1.02 ± 0.08
TKTL1 8.62 ± 0.92 8.43 ± 0.78 0.15 ± 0.02 1.03 ± 0.11 0.17 ± 0.03
TKTL 2 0.89 ± 0.10 1.12 ± 0.13 1.06 ± 0.11 0.99 ± 0.07 1.02 ± 0.09
The expression level of transketolase gene family members was analyzed using real-time quantitative PCR. The relative expression amount of target 
gene in the HeLa and End1/E6E7 cells was calculated using the 2 -ΔΔCT method. The relative expression amount of target gene in the HeLa cell was 
normalized to β-actin and relative to the expression of End1/E6E7 cells untreated. The relative expression amount of target gene in the End1/E6E7 
cells (transfected with control plasmid and transfected with siRNA) was normalized to β-actin and relative to the expression of cells untreated.
The effect of anti-TKTL1 siRNA on transketolase activity in  the HeLa cells and End1/E6E7 cells Figure 2
The effect of anti-TKTL1 siRNA on transketolase 
activity in the HeLa cells and End1/E6E7 cells. 1: the 
cells without transfection, 2: the cells transfected control 
plasmid, 3: the cells transfected siRNA. The total transketo-
lase activity was significantly increased in the HeLa cells with-
out transfection compared to that in the End1/E6E7 cells 
without transfection. The total transketolase activity was sig-
nificantly decreased in the HeLa cells transfected siRNA. 
There were no significant difference existed in total transke-
tolase activity after transfected siRNA in the End1/E6E7 cells.Journal of Experimental & Clinical Cancer Research 2009, 28:43 http://www.jeccr.com/content/28/1/43
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significantly inhibited; there was no significant change in
normal cervical epithelial cells. We think that the most
effective way to inhibit tumor proliferation should be to
block the generation of energy or nucleic acids for tumor
growth. So, we believe TKTL1 gene might become a novel
hot spot of study in anticancer therapy.
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Table 2: The effect of siRNA TKTL1 on cell cycle in the End1/E6E7 cells and HeLa cells (The number of cells, %)
No transfection Control plasmid siRNA
End1/E6E7 cells M1:3.26 ± 0.12 5.12 ± 0.18 5.32 ± 0.16
M2:72.68 ± 3.52 71.96 ± 3.26 72.38 ± 3.45
M3:11.32 ± 0.68 10.84 ± 0.62 11.24 ± 0.63
M4:12.74 ± 0.72 12.08 ± 0.70 11.06 ± 0.66
HeLa cells M1:4.07 ± 0.16 4.62 ± 0.23 5.57 ± 0.21
M2:54.24 ± 2.36 55.36 ± 2.75 69.02 ± 2.98
M3:15.71 ± 0.78 15.84 ± 0.81 15.93 ± 0.84
M4:25.98 ± 1.24 24.18 ± 1.16 9.48 ± 0.56
M1: the percentage of apoptotic cells, M2: G0/G1 stage cells, M3: S stage cells, M4: G2/M stage cells. In the End1/E6E7 cells, there was no significant 
difference existed in cell cycle among the cells without transfection, transfected with control plasmid and transfected with siRNA. In the HeLa cells, 
after transfection with siRNA TKTL1, the percentage of G0/G1 stage cells was increased, the percentage of G2/M stage cells was significantly 
reduced.
The effect of anti-TKTL1 siRNA on proliferation of End1/E6E7 cells and HeLa cells Figure 3
The effect of anti-TKTL1 siRNA on proliferation of End1/E6E7 cells and HeLa cells. In the End1/E6E7 cells (A), 
There was no significant difference of cell proliferation among the cells without transfection, transfected with control plasmid 
and transfected with siRNA. In the HeLa cells (B), cell proliferation was significantly inhibited after transfected siRNA TKTL1 
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